Use of cdk9 and brd4 inhibitors to inhibit inflammation
AssigneeThe Regents of the University of California
InventorsDominik HAUDENSCHILD, Jasper YIK
Life of this patent
Estimating the term…
Abstract
Provided are methods for the combined use of cyclin-dependent kinase 9 (CDK9) inhibitors and bromodomain containing 4 (BRD4) inhibitors to reduce, inhibit and/or prevent cartilage degradation and systemic traumatic inflammation. A combination of CDK9 inhibitors and BRD4 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. A combination of CDK9 inhibitors and BRD4 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
Claims24
1-43. (canceled)
A method of treating of reducing or inhibiting inflammation of tissue, comprising:
- administering to a subject an effective amount of a combination comprising
- a CDK9 inhibitor or salt thereof and
- a bromodomain protein 4 (BRD4) inhibitor or a salt thereof,
- wherein the combination provides a synergistic reduction in an inflammation response as compared to either the CDK9 inhibitor or salt thereof or the BRD4 inhibitor or salt thereof when administered alone.
A composition comprising:
- a pharmaceutical formulation of an effective amount of a combination of a CDK9 inhibitor or a salt thereof and an inhibitor of BRD4 or salt thereof,
- wherein the effective amount of the combination provides a synergistic reduction in an inflammation response as compared to either the CDK9 inhibitor or salt thereof or the BRD4 or salt thereof when administered alone.
Dependencies are inferred from the claim text.